PMPRB releases new Guidelines to monitor and review drug prices
| Patented Medicine Prices Review Board Canada | news releases
PMPRB releases new Guidelines to monitor and review drug prices
News results
Showing 1 - 10 of 40 results
PMPRB report reviews potential impact of new medicines on the Canadian market
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.
Anie Perrault to lead PMPRB as Acting Chairperson
| Patented Medicine Prices Review Board Canada | news releases
Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.
PMPRB report shows higher-cost medicines driving a 14.1% growth in private plan drug costs in 2023
| Patented Medicine Prices Review Board Canada | news releases
Report explores the drivers of growth in prescription drug costs for private drug plans
Federal Minister of Health tables the 2023 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
86 new patented medicines were reported to the PMPRB in 2023
PMPRB report reviews new drugs and their potential impact on future drug spending in Canada
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.
PMPRB report examines availability and pricing of new medicines
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.
Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.
PMPRB releases What We Learned Report from recent Policy Roundtable
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) today published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines.
PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures
| Patented Medicine Prices Review Board Canada | news releases
PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.